<DOC>
	<DOCNO>NCT01063829</DOCNO>
	<brief_summary>The aim study find whether AIC246 safe efficacious lower chance cytomegalovirus become active causing illness HBPC transplant ( allogeneic stem cell transplant ) .</brief_summary>
	<brief_title>Safety Efficacy Study New Antiviral Drug Prevent Cytomegalovirus Reactivation Bone Marrow Transplanted Patients</brief_title>
	<detailed_description />
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Seropositive HCMV IgG antibody transplantation First allogeneic Human blood precursor cell ( HBPC ) transplantation perform 1 follow diagnosis : leukaemia , lymphoma , Hodgkin 's lymphoma , nonHodgkin 's lymphoma , multiple myeloma , myelodysplastic myeloproliferative disorder Evidence post transplantation engraftment Able swallow tablet . Previous antiHCMV therapy allogeneic HBPC transplantation Mismatched cord blood transplant recipient Current history endorgan HCMV disease Graft versus host disease ( GVHD ) Impaired liver function Reduced renal function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>HCMV</keyword>
</DOC>